Beam Therapeutics Inc. cash flow to debt ratio of -117.43% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

Beam Therapeutics Inc.'s free cash flow has decreased 1.08% from $-356.19M last year to $-360.05M, signaling decreasing performance

Beam Therapeutics Inc.'s debt to equity ratio is 0.23, which means that the company's assets are healthy financed, signaling financial stability.

Beam Therapeutics Inc.'s debt has increased relative to shareholder equity from 0.22 last year to 0.23 today, signaling weakened financials

Beam Therapeutics Inc. has a net cash position, so leverage is healthy.

Beam Therapeutics Inc.'s interest coverage ratio is -35.53, which means that the company struggles to meet interest obligations, signaling financial risk.

Beam Therapeutics Inc.'s profit margin has increased (-90.77%) in the last year from -593.13% to -54.75%, signaling increasing performance

Beam Therapeutics Inc.'s short-term assets of $1.27B exceed its short-term liabilities of $96.94M

Beam Therapeutics Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

Beam Therapeutics Inc.'s return on equity of -7.70%, is lower than 15.00%, indicating bad performance

Beam Therapeutics Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Beam Therapeutics Inc. had positive net income in only 0 out of 5 years, indicating unstable earnings

Beam Therapeutics Inc. has negative free cash flow, indicating the company is burning cash rather than generating it

Beam Therapeutics Inc. has negative free cash flow, indicating cash burn

Beam Therapeutics Inc.'s yearly earnings has increased -78.77% since last year from $-376.74M to $-79.99M, signaling increasing performance

Beam Therapeutics Inc.'s yearly revenue has increased 120.01% since last year from $63.52M to $139.74M, signaling increasing performance

ROIC -28.62% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

Beam Therapeutics Inc.'s 3-year revenue CAGR of 31.88% is positive, indicating growing revenue over the past 3 years

Beam Therapeutics Inc. had revenue growth in 4 out of 5 years, indicating consistent revenue performance

Beam Therapeutics Inc. had positive ROE in only 0 out of 5 years, indicating inconsistent returns on equity

Beam Therapeutics Inc. has insufficient data to evaluate this check.

Beam Therapeutics Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Beam Therapeutics Inc. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

Beam Therapeutics Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

Beam Therapeutics Inc. is overvalued relative to its fair value price of -151.94 based on Earnings Fair Value model

Beam Therapeutics Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Beam Therapeutics Inc. has a price-to-book ratio of 2.67x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value

Beam Therapeutics Inc. has a price-to-sales ratio of 18.24x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue